Experts warn this is setting up the steepest jump in health care costs in 15 years, with much of the increase expected to hit ...

Lucy D. Mastrandrea, MD, PhD, professor of pediatrics in the Jacobs School of Medicine and Biomedical Sciences, has been ...

There’s a reason why millions of people in the UK are on weight-loss injections – and it’s not because we’re all weak, writes ...

A new University of California San Diego study offers compelling evidence that glucagon-like peptide-1 (GLP-1) receptor ...

Shares of Amgen are up nearly 26% this year and have soared 11% just over the past week.

Did people really mean it when they said being fat is fine, and they don't want to be thin? GLP-1 drugs may be changing this ...

WASHINGTON -- Treatment with the investigational GLP-1/glucagon dual receptor agonist pemvidutide led to resolution of ...

GLP-1 receptor agonists — the drug class that includes Ozempic, Wegovy and Mounjaro — were linked to improved survival among colon cancer patients in a new observational study from UC San Diego.

Oregon and federal leaders must take a dual approach: Expanding safe, affordable access to FDA-approved anti-obesity ...

A new University of California San Diego study offers compelling evidence that glucagon-like peptide-1 (GLP-1) receptor ...

Study also revealed no increased risk for major adverse cardiovascular events for patients on a GLP-1 RA vs those not on a GLP-1 RA.

Opinion: What is Kennedy’s problem with medication?